Cargando…

Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure

BACKGROUND: We determined if the sodium glucose co‐transporter 2 inhibitor empagliflozin attenuates pressure overload‐induced heart failure in non‐diabetic mellitus mice by direct cardiac effects and the mechanisms involved. METHODS AND RESULTS: Male C57BL/6J mice (4–6 months of age) were subjected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xuan, Lu, Qingguo, Qiu, Yunguang, do Carmo, Jussara M., Wang, Zhen, da Silva, Alexandre A., Mouton, Alan, Omoto, Ana C. M., Hall, Michael E., Li, Ji, Hall, John E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174202/ https://www.ncbi.nlm.nih.gov/pubmed/33719499 http://dx.doi.org/10.1161/JAHA.120.018298

Ejemplares similares

Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure
por: Li, Xuan, et al.
Publicado: (2022)

Temporal changes in glucose metabolism reflect polarization in resident and monocyte-derived macrophages after myocardial infarction
por: Mouton, Alan J., et al.
Publicado: (2023)

Interaction of Obesity and Hypertension on Cardiac Metabolic Remodeling and Survival Following Myocardial Infarction
por: Mouton, Alan J., et al.
Publicado: (2021)

Targeting immunometabolism during cardiorenal injury: roles of conventional and alternative macrophage metabolic fuels
por: Mouton, Alan J., et al.
Publicado: (2023)

Transient receptor potential cation channel 6 contributes to kidney injury induced by diabetes and hypertension
por: Wang, Zhen, et al.
Publicado: (2022)

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
por: Lee, Ting-I, et al.
Publicado: (2019)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Restoration of Cardiac Function After Myocardial Infarction by Long-Term Activation of the CNS Leptin-Melanocortin System
por: Gava, Fabio N., et al.
Publicado: (2021)

Central Nervous System Actions of Leptin Improve Cardiac Function After Ischemia–Reperfusion: Roles of Sympathetic Innervation and Sex Differences
por: Omoto, Ana C. M., et al.
Publicado: (2022)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Sodium–Glucose cotransporter 2 inhibitor empagliflozin decreases ventricular arrhythmia susceptibility by alleviating electrophysiological remodeling post-myocardial-infarction in mice
por: Xue, Genlong, et al.
Publicado: (2022)

Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
por: Philippaert, Koenraad, et al.
Publicado: (2021)

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats
por: Kuno, Atsushi, et al.
Publicado: (2020)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
por: Lee, Hsiang-Chun, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
por: Sanon, Vani P, et al.
Publicado: (2017)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
por: Li, Chenguang, et al.
Publicado: (2019)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
por: Biancalana, Edoardo, et al.
Publicado: (2023)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
por: Scisciola, Lucia, et al.
Publicado: (2023)

Effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure
por: Beusekamp, Joost C., et al.
Publicado: (2021)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
por: Wang, Dong-Dong, et al.
Publicado: (2022)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload
por: Nakao, Masaaki, et al.
Publicado: (2021)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Multiple Evanescent White Dot Syndrome Presenting After Initiation of Empagliflozin, a Sodium-Glucose Cotransporter-2 Inhibitor
por: Boutros, Heidi, et al.
Publicado: (2021)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Leptin reverses hyperglycemia and hyperphagia in insulin deficient diabetic rats by pituitary-independent central nervous system actions
por: da Silva, Alexandre A., et al.
Publicado: (2017)

Continuing Treatment with Salvia miltiorrhiza Injection Attenuates Myocardial Fibrosis in Chronic Iron-Overloaded Mice
por: Zhang, Ying, et al.
Publicado: (2015)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events
por: Xie, Yan, et al.
Publicado: (2020)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oj1uuiljrv39hlkplajt00stev